Skip to content
Quebec News Tribune – Lifestyle
Author:
BridgeBio Pharma, Inc.
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
May 12, 2026
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
May 11, 2026
←
Previous Page
1
2
3
4